TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22109783

Group type: EXPERIMENTAL
Intervention: Physical activity program for preschool children, including structured activities and professional development for staff.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care activities (control group)
Number of subjects: 0
Study: 19856790

Group type: EXPERIMENTAL
Intervention: Test formulation of cetirizine hydrochloride
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation of cetirizine hydrochloride
Number of subjects: 18
Study: 17572834

Group type: EXPERIMENTAL
Intervention: Foot stamping, progressively loaded squats, and in‐line dancing
Number of subjects: 45
Study: 14747227

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor (ARI) zopolrestat 500 or 1,000 mg daily for 1 year
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 11154482

Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 9663180

Group type: EXPERIMENTAL
Intervention: 200 mg/day oral fluconazole
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluconazole and Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 25
Study: 8142663

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both Ganciclovir and Placebo
Number of subjects: 47
Study: 3146891

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 47

Group type: COMPARATOR
Intervention: L-5-hydroxytryptophan (L-5HTP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nomifensine
Number of subjects: 47
Study: 31770784

Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 73

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 73
Study: 31539064

Group type: EXPERIMENTAL
Intervention: Maternal history of chorioamnionitis
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prolonged rupture of membrane
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Multiple digital vaginal examinations during labor
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Neonatal history of perinatal asphyxia
Number of subjects: 105
Study: 31093954

Group type: EXPERIMENTAL
Intervention: Plasma Neurotensin (NTS)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Loge (plasma NTS concentration)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Loge (Age)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 165
Study: 28777984

Group type: EXPERIMENTAL
Intervention: Comorbid nightmare disorder
Number of subjects: 379

Group type: COMPARATOR
Intervention: No comorbid nightmare disorder
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Comorbid sleep terror disorder
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Comorbid sleepwalking disorder
Number of subjects: 379
Study: 25421472

Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily for 6 days
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily for 10 days
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Tedizolid
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 1333
Study: 24078554

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 1 mg·kg(‐1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 62
Study: 21595951

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by surgery (CS group)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Surgery alone (S group)
Number of subjects: 169
Study: 19673614

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg twice daily for 4 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 16275011

Group type: EXPERIMENTAL
Intervention: Adjusted analysis with prespecified covariate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted analysis with significant predictive strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted analysis with significant imbalance strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unadjusted analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covariate HR between 2 and 5
Number of subjects: 0
Study: 29932413

Group type: EXPERIMENTAL
Intervention: 0.5-mg DuvieTM tablets (test drug)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.5-mg DuvieTM tablets (reference drug)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 28
Study: 10619929

Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated cardiopulmonary bypass circuits
Number of subjects: 24

Group type: COMPARATOR
Intervention: Noncoated equipment (control group)
Number of subjects: 24
Study: 8616766

Group type: EXPERIMENTAL
Intervention: CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin)
Number of subjects: 253

Group type: COMPARATOR
Intervention: melphalan
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: CHAD
Number of subjects: 253
Study: 1826237

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of unmodified insulin (10 U)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of unmodified insulin (10 U)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypoglycaemia
Number of subjects: 8
Study: 7122669

Group type: EXPERIMENTAL
Intervention: 400 mg valerian extract
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Proprietary valerian-containing preparation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 29528962

Group type: EXPERIMENTAL
Intervention: 1 session·wk per muscle group (G1, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 sessions·wk per muscle group (G2, n = 10)
Number of subjects: 20
Study: 30241510

Group type: EXPERIMENTAL
Intervention: CYD‐TDV standard 0‐6‐12 months schedule
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: CYD‐TDV accelerated 0‐2‐6 months schedule
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: CYD‐TDV accelerated schedule with YF co‐administered
Number of subjects: 390

Group type: COMPARATOR
Intervention: YF vaccination only
Number of subjects: 390
Study: 27662279

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 24576515

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen 6 L/min delivered by Oxymask for 6 to 12 hours
Number of subjects: 6600

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 6600
Study: 22569622

Group type: EXPERIMENTAL
Intervention: ETT intracuff 2% lidocaine plus 8.4% sodium bicarbonate (L group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ETT intracuff 0.9% saline (S group)
Number of subjects: 50
Study: 20385439

Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate sinus floor graft with simultaneous implant insertion
Number of subjects: 62

Group type: COMPARATOR
Intervention: Posterior maxilla implants without sinus lift
Number of subjects: 62
Study: 19238877

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.4 mg/day) starting at least one month before conception and continuing for the first quarter of pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food fortification strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Promotion of healthy dietary habits
Number of subjects: 0
Study: 15989166

Group type: EXPERIMENTAL
Intervention: Various interventions aimed at increasing physical activity and lowering dietary fat; specific dosages and durations not available.
Number of subjects: 30
Study: 12024134

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam plus meperidine
Number of subjects: 80
Study: 10509552

Group type: EXPERIMENTAL
Intervention: Fosinopril and HCTZ with nabumetone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fosinopril and HCTZ with sulindac
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fosinopril and HCTZ with ibuprofen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Acetaminophen (washout period)
Number of subjects: 17
Study: 7815656

Group type: EXPERIMENTAL
Intervention: Zalcitabine at 0.75 mg every 8 hours
Number of subjects: 338

Group type: COMPARATOR
Intervention: Zidovudine at 200 mg (later 100 mg) every 4 hours
Number of subjects: 338
Study: 1901808

Group type: EXPERIMENTAL
Intervention: 300 mg ponalrestat
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 600 mg ponalrestat
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 7179208

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (s.c.) administered as two daily injections
Number of subjects: 141

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of heparin (i.v.)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (s.c.)
Number of subjects: 141
Study: 31761539

Group type: EXPERIMENTAL
Intervention: LHe 5.6 M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LHe 6.6 M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LN 5.6 M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LN 6.6 M
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 0
Study: 29165558

Group type: EXPERIMENTAL
Intervention: Paro (robotic seal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plush Toy (non-robotic)
Number of subjects: 20
Study: 28353579

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 88
Study: 26890736

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metformin maximum dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metformin and Placebo
Number of subjects: 80
Study: 25243773

Group type: EXPERIMENTAL
Intervention: Single-mechanism model for decision making based on parallel constraint satisfaction processes (PCS-DM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-strategy account
Number of subjects: 0
Study: 22906808

Group type: EXPERIMENTAL
Intervention: Self-experience multidisciplinary lifestyle intervention
Number of subjects: 77
Study: 21149923

Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg once daily
Number of subjects: 689

Group type: COMPARATOR
Intervention: LPV/r 800/200 mg total daily dose
Number of subjects: 689
Study: 17284514

Group type: EXPERIMENTAL
Intervention: Acetaminophen 90-100 mg kg(‐1) day(‐1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16084880

Group type: EXPERIMENTAL
Intervention: Low-dose hCG (200 IU/day) alone after ovarian priming with recombinant FSH/hMG (group B)
Number of subjects: 0
Study: 12126926

Group type: EXPERIMENTAL
Intervention: Pentaspan (500 ml, infusion condition)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (60 ml saline, non-infusion condition)
Number of subjects: 12
Study: 10402256

Group type: EXPERIMENTAL
Intervention: Visual imagery of letters
Number of subjects: 10

Group type: COMPARATOR
Intervention: Detection of intervening tones
Number of subjects: 10
Study: 1414961

Group type: EXPERIMENTAL
Intervention: 4.25‐MJ/d liquid diet supplemented with pyruvate (PY; n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (PY and placebo)
Number of subjects: 14
Study: 3887551

Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30466714

Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: HRV biofeedback + autogenic training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 78
Study: 30672192

Group type: EXPERIMENTAL
Intervention: Conventional drug therapy combined with acupuncture (Baihui, Sishencong, Neiguan, Hegu, Taixi), treatment given once daily, 6 times a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional drug therapy only, treatment given once daily, 6 times a week for 4 weeks.
Number of subjects: 60
Study: 27129849

Group type: EXPERIMENTAL
Intervention: Progressive training intervention comprising 8 supervised group sessions and home exercises (2/week over 11 weeks)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group (ratio 10:1 control vs. intervention)
Number of subjects: 1400
Study: 26443290

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 260
Study: 24251308

Group type: EXPERIMENTAL
Intervention: RVOT lead position
Number of subjects: 132

Group type: COMPARATOR
Intervention: RVA lead position
Number of subjects: 132
Study: 21472645

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 0
Study: 18307628

Group type: EXPERIMENTAL
Intervention: Atrial-based pacing mode (VDD or DDD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ventricular demand pacing mode (VVI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitroglycerin-mediated vasodilation
Number of subjects: 12
Study: 16540869

Group type: EXPERIMENTAL
Intervention: Subtotal discectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Limited discectomy
Number of subjects: 30
Study: 20217660

Group type: EXPERIMENTAL
Intervention: RNP clinic
Number of subjects: 80

Group type: COMPARATOR
Intervention: JHD clinic
Number of subjects: 80
Study: 10634364

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9447898

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 112
Study: 8182195

Group type: EXPERIMENTAL
Intervention: Resin composite inlays
Number of subjects: 240

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 240
Study: 2906699

Group type: EXPERIMENTAL
Intervention: Urapidil 15-60 mg twice a day for 8 weeks or more
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Urapidil 15-60 mg twice a day for 1 year or more (monotherapy)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Urapidil 15-60 mg twice a day for 1 year or more (combined therapy with thiazide)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Urapidil (both monotherapy and combined therapy)
Number of subjects: 129
Study: 29274840

Group type: EXPERIMENTAL
Intervention: closed-NPWT
Number of subjects: 49

Group type: COMPARATOR
Intervention: open-NPWT
Number of subjects: 49
Study: 28641703

Group type: COMPARATOR
Intervention: Minimum follow-up (n=301)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: CEA testing only (n=300)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: CT only (n=299)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: CEA testing and CT (n=302)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Overall (intensive follow-up arms)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Overall (minimum follow-up)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Survival analysis
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of CEA testing
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of CT
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of CEA testing and CT
Number of subjects: 1202
Study: 25335247

Group type: EXPERIMENTAL
Intervention: Low-frequency electric stimulation at acupoints (Dazhui (GV 14) and Shenshu (BL 23)), once a day for 15 days, 2 sessions total.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estazolam, 1 mg orally before sleep for 15 days, 2 sessions total.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (starch capsules, 1 capsule orally before sleep for 15 days, 2 sessions total).
Number of subjects: 120
Study: 23403549

Group type: EXPERIMENTAL
Intervention: X‐Stop
Number of subjects: 100

Group type: COMPARATOR
Intervention: Decompression
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 20132285

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 17920108

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy using cisplatin/cyclophosphamide or cisplatin/paclitaxel chemotherapy
Number of subjects: 151
Study: 16629278

Group type: EXPERIMENTAL
Intervention: Standardized Patients (SPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual method of instruction
Number of subjects: 0
Study: 14636967

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Behavioral group counseling
Number of subjects: 353
Study: 10651430

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (4 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 8862952

Group type: EXPERIMENTAL
Intervention: Metformin treatment (850 mg three times daily for 12 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 27
Study: 1308476

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) infusion (600 mg every day for seven days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6427827

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Imipramine‐N‐oxide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isocarboxazide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 11
Study: 30878983

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30185210

Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional intervention control
Number of subjects: 54
Study: 27228432

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN), n=36
Number of subjects: 69

Group type: COMPARATOR
Intervention: SHAM treatment, n=33
Number of subjects: 69
Study: 24560188

Group type: EXPERIMENTAL
Intervention: Successful weight reduction (n = 20)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Unsuccessful weight reduction (n = 27)
Number of subjects: 57
Study: 23131255

Group type: EXPERIMENTAL
Intervention: Low-dose linezolid treatment for MDR-TB (16 weeks, daily dosage)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study: 20678686

Group type: EXPERIMENTAL
Intervention: Test formulation of atorvastatin (20 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reference formulation of atorvastatin (20 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Test formulation of ortho-hydroxy-atorvastatin (20 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reference formulation of ortho-hydroxy-atorvastatin (20 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both formulations of atorvastatin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both formulations of ortho-hydroxy-atorvastatin
Number of subjects: 46
Study: 17660388

Group type: EXPERIMENTAL
Intervention: Systemic infusion of L-NMMA (10 mg/kg)
Number of subjects: 20
Study: 15711037

Group type: EXPERIMENTAL
Intervention: Pre-dilution CVVH
Number of subjects: 31

Group type: COMPARATOR
Intervention: Post-dilution CVVH
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nadroparin (NP) pre-filter
Number of subjects: 31

Group type: COMPARATOR
Intervention: Heparin-protamine (HP) post-filter
Number of subjects: 31
Study: 12413113

Group type: EXPERIMENTAL
Intervention: Educational video and written instructions
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 500
Study: 10070942

Group type: EXPERIMENTAL
Intervention: Annual screening (6 guaiac-impregnated fecal occult blood tests)
Number of subjects: 46551

Group type: EXPERIMENTAL
Intervention: Biennial screening (6 guaiac-impregnated fecal occult blood tests)
Number of subjects: 46551

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 46551
Study: 8849355

Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2339674

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 322562

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 44
Study: 31264269

Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses with increased compression factor (1.75 D)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Orthokeratology lenses with lower compression factor (0.75 D)
Number of subjects: 28
Study: 31011270

Group type: EXPERIMENTAL
Intervention: 7Ps elements (product, place, promotion, people, physical assets, process management)
Number of subjects: 235
Study: 28553094

Group type: EXPERIMENTAL
Intervention: Standard training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prototype device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard training and Prototype device
Number of subjects: 30